{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:39:55Z","timestamp":1775576395061,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Epidemiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Congenital cytomegalovirus (CMV) infection is the leading cause of hearing loss and neurocognitive delay among children. Affected infants may be asymptomatic at birth and even pass their universal hearing screen. Early identification of CMV-infected infants will allow earlier detection, evaluation and management. The prevalence of congenital CMV infection in the developed world varies geographically from 0.6% to 0.7% of all deliveries and certain regions are at higher risk. The prevalence of congenital CMV is unknown for our region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>The purpose of this study was to determine the prevalence of CMV infection among the neonatal population at an urban, tertiary hospital in northeast Florida which serves a large population of patients with low socioeconomic status to assess if universal screening program for congenital asymptomatic CMV infection can be determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was submitted and approved by our Institutional Review Board. We tested the urine for CMV infection in 100 asymptomatic newborns (&amp;gt;32 weeks gestational age and &amp;gt;1,750\u2005g weight at the time of delivery) delivered between June 2016 and July 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Urine CMV was tested on 100 infants. One infant had a positive urine NAAT for CMV, making the prevalence of congenital CMV infection among asymptomatic newborns in our hospitals' population 1%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CMV prevalence in our setting of an urban, tertiary hospital is relatively consistent with the national average of all congenital CMV infections. A policy of universal screening for congenital CMV may be necessary.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fepid.2023.1270374","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T04:33:10Z","timestamp":1704256390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of asymptomatic cytomegalovirus (CMV) infection in newborns in northeast Florida"],"prefix":"10.3389","volume":"3","author":[{"given":"Rana","family":"Alissa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar","family":"Maraqa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patty D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Hipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sfurti","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole S.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Matoq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mobeen","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMra050700","article-title":"Newborn hearing screening\u2013a silent revolution","volume":"354","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/s0022-3476(97)70248-8","article-title":"Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection","volume":"130","author":"Fowler","year":"1997","journal-title":"J Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s0022-3476(99)70328-8","article-title":"Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?","volume":"135","author":"Fowler","year":"1999","journal-title":"J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jcv.2005.09.016","article-title":"Congenital cytomegalovirus (CMV) infection and hearing deficit","volume":"35","author":"Fowler","year":"2006","journal-title":"J Clin Virol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00023-08","article-title":"Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention","volume":"22","author":"Cheeran","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.pcl.2012.12.008","article-title":"Congenital cytomegalovirus infection: new prospects for prevention and therapy","volume":"60","author":"Swanson","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1055\/s-0042-1748054","article-title":"Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus","volume":"11","author":"Dahle","year":"2000","journal-title":"J Am Acad Audiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1093\/cid\/cit629","article-title":"Congenital cytomegalovirus infection: clinical outcome","author":"Boppana","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e20162610","DOI":"10.1542\/peds.2016-2610","article-title":"Congenital cytomegalovirus longitudinal study group. Hearing loss in children with asymptomatic congenital cytomegalovirus infection","volume":"139","author":"Lanzieri","year":"2017","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcv.2007.09.004","article-title":"Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment","volume":"41","author":"Grosse","year":"2008","journal-title":"J Clin Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1056\/NEJMoa1006561","article-title":"National institute on deafness and other communication disorders CHIMES study. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns","volume":"364","author":"Boppana","year":"2011","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2022059895","DOI":"10.1542\/peds.2022-059895","article-title":"Considering antiviral treatment to preserve hearing in congenital CMV","volume":"151","author":"Lanzieri","year":"2023","journal-title":"Pediatrics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1086\/516445","article-title":"Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National institute of allergy and infectious diseases collaborative antiviral study group","volume":"175","author":"Whitley","year":"1997","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/clpt.1993.4","article-title":"Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID collaborative antiviral study group","volume":"53","author":"Trang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1128\/AAC.40.9.2202","article-title":"Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID collaborative antiviral study group","volume":"40","author":"Zhou","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/s0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1542\/9781581109276-Cytomegalovirus","article-title":"Cytomegalovirus infection","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2015"},{"key":"B22","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1093\/cid\/cit609","article-title":"Congenital cytomegalovirus infection: audiologic outcome","author":"Fowler","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"909646","DOI":"10.3389\/fped.2022.909646","article-title":"Universal newborn screening for congenital cytomegalovirus infection\u2014from infant to maternal infection: a prospective multicenter study","volume":"10","author":"Chiereghin","year":"2022","journal-title":"Front Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"key":"B26","first-page":"35","article-title":"U.S. Public health impact of congenital cytomegalovirus infection","volume":"41","year":"1992","journal-title":"MMWR\u2014CDC Surveillance Summaries"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamapediatrics.2016.2016","article-title":"Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection","volume":"170","author":"Gantt","year":"2016","journal-title":"JAMA Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1086\/323677","article-title":"Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the ashkenazi Jewish population","volume":"69","author":"Edelmann","year":"2001","journal-title":"Am J Hum Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40246-022-00398-9","article-title":"Genetic etiology and clinical challenges of phenylketonuria","volume":"16","author":"Elhawary","year":"2022","journal-title":"Hum Genomics"},{"key":"B31","year":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1259","DOI":"10.1542\/peds.2011-1317","article-title":"Strategies for implementing screening for critical congenital heart disease","volume":"128","author":"Kemper","year":"2011","journal-title":"Pediatrics"}],"container-title":["Frontiers in Epidemiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2023.1270374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T04:33:12Z","timestamp":1704256392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2023.1270374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":32,"alternative-id":["10.3389\/fepid.2023.1270374"],"URL":"https:\/\/doi.org\/10.3389\/fepid.2023.1270374","relation":{},"ISSN":["2674-1199"],"issn-type":[{"value":"2674-1199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"article-number":"1270374"}}